Certara Inc. Stock Analysis CERT

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,515 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.